Liu Yang, Ye Xinyu, Zhang Hong, Xu Xiaogang, Li Wanhua, Zhu Demei, Wang Minggui
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, PR China.
Diagn Microbiol Infect Dis. 2010 Aug;67(4):355-8. doi: 10.1016/j.diagmicrobio.2010.03.004.
One hundred Mycoplasma pneumoniae strains were isolated from pediatric patients from March 2008 to July 2009. Of 100 isolates, 90 (90%) were resistant to erythromycin (MICs >128 microg/mL for 88 strains and 64 microg/mL for 2 strains), azithromycin, and clarithromycin. Fluoroquinolones and tetracyclines maintain good activities against clinical M. pneumoniae isolates. Of 90 macrolide-resistant M. pneumoniae strains, 88 (98%) harbored an A-to-G transition mutation at position 2063 in 23S rRNA genes, and the remaining 2 showed either A2064G or A2063T mutation; the latter point mutation is newly discovered and reported. Ninety-three (93%) clinical isolates were classified into the P1 gene restriction fragment length polymorphism (RFLP) type I, and 7 (7%) were type II.
2008年3月至2009年7月期间,从儿科患者中分离出100株肺炎支原体菌株。在这100株分离株中,90株(90%)对红霉素(88株的最低抑菌浓度>128μg/mL,2株为64μg/mL)、阿奇霉素和克拉霉素耐药。氟喹诺酮类和四环素类药物对临床肺炎支原体分离株仍保持良好活性。在90株对大环内酯类耐药的肺炎支原体菌株中,88株(98%)在23S rRNA基因的2063位发生了A到G的转换突变,其余2株表现为A2064G或A2063T突变;后一种点突变是新发现并报道的。93株(93%)临床分离株被归类为P1基因限制性片段长度多态性(RFLP)I型,7株(7%)为II型。